Antihypertensive background therapy at baseline, n (%) | 15 (75) | 3 (60) |
RAS inhibitors, n (%) | 13 (87) | 2 (67) |
ACEIs, n | 4 | 0 |
ARBs, n | 9 | 2 |
ACEI+ARB, n | 1 | 0 |
Spironolactone, n | 2 | 0 |
Ca antagonists, n (%) | 11 (73) | 3 (60) |
Diuretics, n (%) | 0 (0) | 1 (20) |
β blockers, n (%) | 1 (7) | 1 (20) |
α-Methyldopa, n (%) | 2 (13) | 0 |